{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GSK1349572+%28dolutegravir%29&page=2", "query": { "intervention": "GSK1349572 (dolutegravir)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 147, "total_pages": 15, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GSK1349572+%28dolutegravir%29&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GSK1349572+%28dolutegravir%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-04T21:51:43.133Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00858455", "title": "A Study to Evaluate the Effect of Antacid and Multivitamin and Mineral Tablet on the Study Drug GSK1349572", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer" ], "interventions": [ { "name": "GSK1349572 and MaaloxAdvanced Maximum Strength", "type": "DRUG" }, { "name": "GSK1349572 and Maalox Advanced Maximum Strength", "type": "DRUG" }, { "name": "GSK1349572 and One A Day", "type": "DRUG" }, { "name": "GSK1349572", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 16, "start_date": "2009-01", "completion_date": "2009-03", "has_results": false, "last_update_posted_date": "2009-06-05", "last_synced_at": "2026-10-04T21:51:43.133Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00858455" }, { "nct_id": "NCT01231529", "title": "GSK1349572 Hepatic Impairment Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Subjects", "Hepatic Impairment", "Infection, Human Immunodeficiency Virus", "HIV Infections" ], "interventions": [ { "name": "GSK1349572", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 16, "start_date": "2010-11-19", "completion_date": "2011-06-04", "has_results": false, "last_update_posted_date": "2019-07-31", "last_synced_at": "2026-10-04T21:51:43.133Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01231529" }, { "nct_id": "NCT06630299", "title": "Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1-Infection" ], "interventions": [ { "name": "ISL/LEN", "type": "DRUG" }, { "name": "Antiretroviral Combinations", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 600, "start_date": "2024-10-08", "completion_date": "2030-08", "has_results": false, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-10-04T21:51:43.133Z", "location_count": 49, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 41 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palm Springs", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06630299" }, { "nct_id": "NCT04272242", "title": "Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infection", "LTBI" ], "interventions": [ { "name": "Dolutegravir (DTG)", "type": "DRUG" }, { "name": "Isoniazid (INH)", "type": "DRUG" }, { "name": "Rifapentine (RPT)", "type": "DRUG" }, { "name": "Antiretroviral Therapy (ART)", "type": "DRUG" }, { "name": "Pyridoxine (Vitamin B6)", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 37, "start_date": "2021-02-27", "completion_date": "2021-12-27", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-10-04T21:51:43.133Z", "location_count": 2, "location_summary": "San Francisco, California • Houston, Texas", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04272242" }, { "nct_id": "NCT02121795", "title": "Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "FTC/TDF", "type": "DRUG" }, { "name": "F/TAF", "type": "DRUG" }, { "name": "Allowed third antiretroviral agent", "type": "DRUG" }, { "name": "FTC/TDF Placebo", "type": "DRUG" }, { "name": "F/TAF Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 668, "start_date": "2014-05-06", "completion_date": "2019-03-01", "has_results": true, "last_update_posted_date": "2020-03-12", "last_synced_at": "2026-10-04T21:51:43.133Z", "location_count": 57, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 40 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Hayward", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02121795" }, { "nct_id": "NCT01449929", "title": "Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "dolutegravir 50 mg OAD", "type": "DRUG" }, { "name": "darunavir 800mg OAD", "type": "DRUG" }, { "name": "ritonavir 100mg OAD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 488, "start_date": "2011-10-31", "completion_date": "2016-12-26", "has_results": true, "last_update_posted_date": "2018-01-16", "last_synced_at": "2026-10-04T21:51:43.133Z", "location_count": 33, "location_summary": "Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01449929" }, { "nct_id": "NCT01563328", "title": "A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (ING115697).", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "DTG", "type": "DRUG" }, { "name": "BCV", "type": "DRUG" }, { "name": "TVR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 32, "start_date": "2012-03-01", "completion_date": "2012-05-01", "has_results": false, "last_update_posted_date": "2017-03-28", "last_synced_at": "2026-10-04T21:51:43.133Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01563328" }, { "nct_id": "NCT07683000", "title": "Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1-infection" ], "interventions": [ { "name": "Lenacapavir", "type": "DRUG" }, { "name": "Lenacapavir Tablet", "type": "DRUG" }, { "name": "Teropavimab", "type": "DRUG" }, { "name": "Zinlirvimab", "type": "DRUG" }, { "name": "SBR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 590, "start_date": "2026-07-14", "completion_date": "2033-03", "has_results": false, "last_update_posted_date": "2026-07-30", "last_synced_at": "2026-10-04T21:51:43.133Z", "location_count": 2, "location_summary": "Berkeley, Michigan • Annandale, Virginia", "locations": [ { "city": "Berkeley", "state": "Michigan" }, { "city": "Annandale", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07683000" }, { "nct_id": "NCT02603120", "title": "Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "ABC/DTG/3TC", "type": "DRUG" }, { "name": "B/F/TAF", "type": "DRUG" }, { "name": "ABC/DTG/3TC Placebo", "type": "DRUG" }, { "name": "B/F/TAF Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 567, "start_date": "2015-11-11", "completion_date": "2019-10-23", "has_results": true, "last_update_posted_date": "2020-11-12", "last_synced_at": "2026-10-04T21:51:43.133Z", "location_count": 61, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 48 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02603120" }, { "nct_id": "NCT02539576", "title": "Pharmacokinetics, Safety and Tolerability Study of Abacavir/ Dolutegravir/ Lamivudine Fixed-dose Combination Tablets in Healthy Japanese Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "ABC/DTG/3TC FDC tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 12, "start_date": "2015-10", "completion_date": "2015-11", "has_results": false, "last_update_posted_date": "2015-12-21", "last_synced_at": "2026-10-04T21:51:43.133Z", "location_count": 1, "location_summary": "Glendale, California", "locations": [ { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02539576" } ] }